Showing 1 - 3 results of 3 for search 'Pratyush Giri', query time: 0.03s Refine Results
  1. 1
    Paraneoplastic acute fibrinous and organizing pneumonia from lymphoma completely responding to bendamustine‐rituximab

    Paraneoplastic acute fibrinous and organizing pneumonia from lymphoma completely responding to bendamustine‐rituximab by Thomas Crowhurst, Pratyush Giri, Caroline Smith, Phan Nguyen, Paul Reynolds

    Published 2020-12-01
    Get full text
    Article
  2. 2
    P625: A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

    P625: A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPH... by John C. Byrd, Seema Ali Bhat, Farrukh Awan, Pratyush Giri, Sumita Ratnasingam, Roman Hájek, Dagmar Hess, Daniela Alves, Jan Maciej Zaucha, Annalise Shen, Elizabeth Bilotti, Jesse Mcgreivy, Wayne P. Rothbaum, Hanna Ciepluch

    Published 2023-08-01
    Get full text
    Article
  3. 3
    P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY

    P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALY... by Adrian Minson, Emma Verner, Pratyush Giri, Shu Min Wong, Sumita Ratnasingam, Jason Butler, Wojciech Janowski, Matthew Ku, Chan Cheah, Mark Hertzberg, Kirsten Herbert, Nada Hamad, Costas Yannakou, Paul Neeson, Javad Saghebi, Piers Blombery, Molly Robertson, Lei Shong Lau, Jing Xie, John Seymour, Michael Dickinson

    Published 2023-08-01
    Get full text
    Article

Search Tools: